Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, is the lead author of a new article reporting on a study that found prolonged elevation of hepatic biomarkers and fibrosis (scarring) scores is associated with a greater risk of negative clinical outcomes in patients with primary … Read more
Velocity is collaborating with Merck to enhance the way trial insights are shared within Merck and across Velocity sites worldwide. Through fast-response data exchange, we’ve developed the Velocity Insight Platform (VIP), a dynamic dashboard that provides actionable metrics to optimize site activities. A huge … Read more
Nadege Gunn, MD, CPI, DABOM, FAASLD, has been named a Fellow of the American Association for the Study of Liver Diseases (AASLD)! This designation is the highest honor awarded to AASLD members and recognizes Dr. Gunn’s exceptional contributions to liver disease research and clinical … Read more
Clinical trials have been steadily leaving the UK for years. In 2021, just 2.2% of patients recruited to global trials were from the UK. By contrast, France, which has a similar population size, accounted for 3.9% that year. That’s not to say we don’t … Read more
Charles Eger, MD, contributed to new research on a combination vaccine intended to provide protection against both seasonal flu and COVID-19 in a single shot. Early results from the Phase 1/2 trial show that the vaccine is well-tolerated and induces strong immune responses, potentially … Read more
Luke Boylan, MBChB, MBA, Principal Investigator at Velocity in North London, recently attended the Parexel Site Alliance Network event. This collaborative gathering included NHS/NIHR-affiliated sites and other commercial research organizations, providing an invaluable opportunity to discuss the evolving landscape of clinical trials in the … Read more
Paul Evans sat down with Patricia Leuchten on the Leaders & Legends podcast, where they discussed the state of research sites and the broader industry. Listen now to hear Paul’s thoughts on: The evolution of clinical research sites and what’s ahead for the industry. … Read more
Women’s health remains one of the most overlooked and underrepresented areas in clinical research, often leading to gaps in treatment and understanding. Similar to obesity research, disorders relating to reproductive health include symptoms that are highly stigmatized and patients can be reluctant to seek … Read more
Craig Koch has been appointed as Velocity’s new Executive Vice President, Europe, to spearhead the next phase of growth across the region. His appointment underscores the company’s long-term commitment to Europe. Previously serving as EVP, Global Head of Sales, Craig has been with Velocity … Read more
Brandon Essink, MD, CPI, is the lead author of study results exploring a next-generation flu vaccine for adults 50+. The published results highlight the potential for combining cell-based approaches and adjuvants to enhance immunogenicity relative to standard flu vaccines on the market. Title: “A … Read more
Congratulations to our Annapolis, MD, site for being recognized as the top U.S. enroller in a Phase 3 respiratory trial. Established in partnership with Luminis Health, this site also marked Velocity’s entry into oncology in the U.S.
Velocity is a nominee for two 2025 Vaccine Industry Excellence (ViE) Awards! After winning the Best Clinical Trial Company ViE Award in 2024, we would be honored to receive your vote and once again share this recognition with you as we work to improve … Read more
Learn more about Velocity's capabilities
Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.
Join a remarkable team doing remarkable work
Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.
Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.